# NAPSTER (NCT05024318)

> NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: clear cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05024318
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: Peter MacCallum Cancer Centre, Australia
- Conditions: Renal Cell Carcinoma, Clear Cell, Somatic
- Interventions: Pembrolizumab; Stereotactic Ablative Radiotherapy; Nephrectomy
- Enrollment: 20
- Primary outcome: mPR post-SABR with or without pembrolizumab
- Primary outcome: CD8+ TRM in baseline biopsy and post-nephrectomy specimen, all measured as a continuous variable.
- Primary outcome: TCF-1 + tumour infiltrating lymphocytes (TILs) in baseline biopsy and post-nephrectomy specimen, measured as a continuous variable

## Indexed commentary on NAPSTER so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 8
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=napster-nct05024318

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05024318", "email": "<work email>"}; the inbox owner confirms by the emailed link.